Featured
Spotlight on Autoimmunity: What is Stiff Person Syndrome?
Watch Time: 04:35
Learn more about Stiff Person Syndrome, what it is and how it manifests. Hear a short overview of current treatment options.
Key Publications
Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T Cell for the Treatment of Autoimmune Disease
Mahne A, et al.
EULAR Congress 2024, Poster #POS0462
Serum Proteomic Analysis Identifies Markers Associated With Anti-CD19 CAR T Therapeutic Response in Autoimmune Diseases
Chou J, et al.
EULAR Congress 2024, Poster #POS0464
Development of Ingenui-T, a Rapid Autologous Chimeric Antigen Receptor (CAR)-T Manufacturing Solution Using Whole Blood, for Treatment of Autoimmune Disease
Anaya D, et al.
ISCT Annual Meeting 2024, Abstract #4070843
Serum Proteomic Analysis Identifies Markers Associated With Anti-CD19 CAR T Therapeutic Response in Autoimmune Diseases
Chou J, et al.
ASGCT 27th Annual Meeting 2024, Abstract #1820
Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T Cell for the Treatment of Autoimmune Disease
Mahne A, et al.
ASGCT 27th Annual Meeting 2024, Abstract #1810
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, et al.
Med. Published online March 29, 2024
First Two US Patients With Lupus Nephritis (LN) Treated With Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy: Preliminary Results From the KYSA-1 Phase 1/2, Multicenter Study of KYV-101
Podoll A, et al.
14th European Lupus Meeting, 2024
Anti-CD19 CAR T cells for refractory myasthenia gravis
Haghikia A, et al.
Lancet Neurology 2023;22:P1104-1105
KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Park S, et al.
ACR Convergence 2023, Abstract #0904
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen A, et al.
Nat Med 2022;28:2424-2132
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Brudno JN, et al.
Nat Med 2020;26:270-280
Meet Kyverna
February 27 - March 1, 2025
West Palm Beach, FL
The annual ACTRIMS Forum highlights novel and rigorous scientific discoveries made in Multiple Sclerosis that advance our understanding of research and clinical care of MS patients. The Forum 2025, themed “Making Connections,” is an opportunity to be inspired, connect with others, and move the conversation forward.
February 6-8, 2025
Strasbourg, France
The meeting covers a broad range of topics spanning the scientific and translational, clinical and commercial development in the field of CAR T. The program will bring you all the latest developments in CAR T cell therapy including previously unpublished clinical data, as well as progress in manufacturing, toxicity modeling, innovative CAR design, CAR delivery methods, and novel applications of CAR T-cell therapy.
Educational Videos
Watch Time: 64:00
Kyverna is proud to sponsor SPSRF’s first podcast, which features Dr. Amanda Piquet, Celine Dion Foundation Endowed Chair and Director of the Autoimmune Neurology Program at the University of Colorado, and The SPSRF Founder, Tara Zier.
Watch Time: 4:22
Learn more about a Phase 2 Trial using an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with Stiff Person Syndrome (SPS) who fail standard therapies. CAR T-cell therapy uses the patient's own immune cells to treat disease.